Joshua Zeidner: Highly impactful data for R/R AML and menin inhibitors
Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post by Ghayas Issa, Leukemia Physician at MD Anderson Cancer Center, on X:
“Glad to see this data finally in print! Congratulations- this is really fantastic. Highly impactful data for a subset of R/R AML with otherwise dismal outcomes. Hoping menin inhibitors may represent a new standard of care.”
Quoting Ghayas Issa‘s post:
“Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval.
Authors: Ghayas C. Issa, Ibrahim Aldoss, Michael J. Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel N. Mannis, Alexander Perl, David S. Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn S. Grove, Richard Stone, Paul J. Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan,Tibor Kovacsovics, Yu Gu, Rebecca G. Bagley, Kate Madigan, Yakov Chudnovsky,Huy Van Nguyen, Nicole McNeer, and Eytan M. Stein.”
Source: Joshua Zeidner/X and Ghayas Issa/X